Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin

被引：0
|
作者：
Miners, John O. [1 ]
Pattanawongsa, Attarat [1 ]
Rowland, Andrew [1 ]
机构：
[1] Flinders Univ S Australia, Coll Med & Publ Hlth, Dept Clin Pharmacol, GPO Box 2100, Adelaide, SA 5001, Australia
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2018年 / 84卷 / 02期
关键词：
canagliflozin; drug-drug interaction; enzyme inhibition; UDP-glucuronosyltransferase; UDP-GLUCURONOSYLTRANSFERASE ENZYMES; GLUCURONIDATION; PHARMACOLOGY; INHIBITION; GUIDE;
D O I：
10.1111/bcp.13443
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：392 / 393
页数：2
相关论文
共 50 条
  • [1] In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin
    Mamidi, Rao N. V. S.
    Dallas, Shannon
    Sensenhauser, Carlo
    Lim, Heng Keang
    Scheers, Ellen
    Verboven, Peter
    Cuyckens, Filip
    Leclercq, Laurent
    Evans, David C.
    Kelley, Michael F.
    Johnson, Mark D.
    Snoeys, Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) : 1082 - 1096
  • [2] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
    Ke, A.
    Callegari, E.
    Bhardwaj, R.
    Varma, M.
    Muto, C.
    Bertz, R.
    Sahasrabudhe, V.
    Liu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S107 - S107
  • [3] Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential
    Patel, Nikunjkumar K.
    Chen, Kuan-Fu
    Chen, Shang-Chiung
    Liu, Kai
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (02): : 317 - 329
  • [4] Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach
    Schaller, Stephan
    Martins, Frederico S.
    Balazki, Pavel
    Bohm, Sonja
    Baumgart, Joachim
    Hilger, Ralf A.
    Beelen, Dietrich W.
    Hemmelmann, Claudia
    Ring, Arne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1722 - 1734
  • [5] Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
    Hanley, Michael J.
    Yeo, Karen Rowland
    Tugnait, Meera
    Iwasaki, Shinji
    Narasimhan, Narayana
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    Gupta, Neeraj
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 624 - 637
  • [6] Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models
    Ryu, Hyo-jeong
    Moon, Hyun-ki
    Lee, Junho
    Yang, Gi-hyeok
    Yang, Sung-yoon
    Yun, Hwi-yeol
    Chae, Jung-woo
    Kang, Won-ho
    PHARMACEUTICALS, 2021, 14 (07)
  • [7] A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SIMULATION OF NALOXEGOL PHARMACOKINETICS AND DRUG-DRUG INTERACTION (DDI) POTENTIAL
    Zhou, D.
    Bui, K.
    Sostek, M.
    Al-Huniti, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S53 - S53
  • [8] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
    de Kanter, Ruben
    Sidharta, Patricia N.
    Delahaye, Stphane
    Gnerre, Carmela
    Segrestaa, Jerome
    Buchmann, Stephan
    Kohl, Christopher
    Treiber, Alexander
    CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 369 - 380
  • [9] Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling
    Min, Jee Sun
    Bae, Soo Kyung
    ARCHIVES OF PHARMACAL RESEARCH, 2017, 40 (12) : 1356 - 1379
  • [10] Physiologically-based pharmacokinetic modelling approach to assess the uptake transporter-mediated drug-drug interaction potential of cyclosporine
    Gertz, Michael
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2010, 42 : 117 - 118
12345